^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
tizetatug rezetecan (SHR-A1921)
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
Related drugs:
Phase 2
Fudan University
Recruiting
Last update posted :
12/27/2024
Initiation :
11/01/2022
Primary completion :
12/31/2024
Completion :
09/01/2025
HER-2 • PGR • CD8 • FOXC1
|
Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Ariely (adebrelimab) • tizetatug rezetecan (SHR-A1921)
Phase 2
Fudan University
Recruiting
Last update posted :
12/10/2024
Initiation :
10/21/2024
Primary completion :
09/01/2026
Completion :
09/01/2027
HER-2 • NECTIN4 • TACSTD2
|
HER-2 expression
|
trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • SHR-A2009 • tizetatug rezetecan (SHR-A1921)
Phase 1/2
Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting
Last update posted :
04/26/2024
Initiation :
05/01/2024
Primary completion :
10/01/2025
Completion :
08/01/2026
KRAS
|
cisplatin • carboplatin • pemetrexed • Ariely (adebrelimab) • HRS-4642 • tizetatug rezetecan (SHR-A1921)
Phase 2
Fudan University
Recruiting
Last update posted :
03/15/2024
Initiation :
07/26/2023
Primary completion :
09/30/2025
Completion :
09/30/2026
HER-2 • AR
|
HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive
|
trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • Airui'en (rezvilutamide) • tizetatug rezetecan (SHR-A1921)
Share
